Axitinib ophthalmic - Clearside Biomedical

Drug Profile

Axitinib ophthalmic - Clearside Biomedical

Alternative Names: CLS 1002; CLS011A

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clearside Biomedical
  • Class Antineoplastics; Eye disorder therapies; Imidazoles; Indazoles; Small molecules
  • Mechanism of Action Platelet-derived growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration

Most Recent Events

  • 14 Mar 2017 Axitinib ophthalmic - Clearside Biomedical is available for licensing as of 14 Mar 2017. www.clearsidebio.com
  • 27 Feb 2017 Clearside Biomedical does not intend to submit an IND to US FDA
  • 05 Jan 2017 Clearside receives notice of allowance for suprachoroidal space drug delivery to treat Eye disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top